The global split-thickness skin grafts (STSG) market for burns and extensive skin loss is experiencing significant growth, driven by the increasing incidence of burn injuries, trauma, and conditions requiring skin reconstruction. Advances in surgical techniques and technologies, such as improved graft harvesting and transplantation methods, are enhancing the effectiveness of split-thickness grafts, making them a preferred choice for reconstructive procedures. The rising awareness of advanced wound care management and the growing prevalence of chronic wounds and skin disorders are further fueling market demand. North America holds a prominent position in the market due to its well-established healthcare infrastructure, high patient awareness, and advancements in medical technology. Meanwhile, the Asia-Pacific region is emerging as a high-growth area, supported by increasing healthcare expenditure and a growing patient population.
Global Split-Thickness Skin Grafts for Burns and Extensive Skin Loss Market is valued at USD 283.88 million in 2023, and is expected to reach USD 588.75 million by 2031 from, with a growing CAGR of 10.0% during the forecast period 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-split-thickness-skin-grafts-for-burns-and-extensive-skin-loss-market
Below are the Top Split-Thickness Skin Grafts For Burns And Extensive Skin Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
MIMEDX Group, Inc.
|
MIMEDX is a pioneer in placental biologics, focusing on delivering innovative solutions for patients and healthcare professionals. With over a decade of experience in managing chronic and hard-to-heal wounds, MIMEDX offers a leading portfolio of products for wound care, burn, and surgical recovery sectors. Their advanced tissue configurations, such as AMNIOBURN, provide alternative treatments for burns, aiming to reduce complications associated with traditional split-thickness skin autografts.
|
|
North America
|
In June 2016, MiMedx Group, Inc., a leading regenerative medicine company specializing in human amniotic tissue and proprietary processes to develop advanced healthcare products and therapies, announced the publication of the latest peer-reviewed independent clinical case series on its EpiFix allografts.
|
|
2.
|
Smith+Nephew
|
Smith+Nephew is a British multinational medical equipment manufacturing company headquartered in Watford, England. The company specializes in advanced wound management products, including skin substitutes and biologics, designed to promote healing in burn and trauma cases. Their commitment to innovation in wound care solutions positions them as a significant player in the global STSG market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In July 2022, Smith+Nephew has launched the WOUND COMPASS Clinical Support App, a digital tool aiding healthcare professionals in wound assessment and decision-making to standardize care and enhance patient outcomes. This initiative strengthens Smith+Nephew's commitment to improving clinical practice and customer satisfaction through innovative digital solutions.
|
|
3.
|
AVITA Medical, Inc.
|
AVITA Medical is a regenerative medicine company focused on developing and commercializing innovative products for the treatment of wounds and skin defects. Their RECELL® System enables the rapid preparation of a patient's own skin cells for application to burn wounds, offering an alternative to traditional split-thickness skin grafts. In June 2024, AVITA announced that the Joseph M. Still Burn Center at Doctors Hospital of Augusta became the first U.S. burn center to treat a patient with its newly FDA-approved RECELL GO System.
|
|
North America, Asia-Pacific, and Europe
|
In June 2024, AVITA Medical, Inc. announced that the Joseph M. Still Burn Center at Doctors Hospital of Augusta is the first U.S. burn center to treat a patient with its newly FDA-approved RECELL GO System, a next-generation autologous cell harvesting device that uses a patient’s own skin to treat thermal burn wounds and full-thickness skin defects. This milestone will help the company by demonstrating the system's effectiveness and expanding its market presence.
|
|
4.
|
B. Braun SE
|
B. Braun SE is a German medical and pharmaceutical device company that offers a range of products, including those for wound care and burn treatment. Their portfolio includes advanced wound dressings and biologics aimed at promoting healing and reducing complications in burn patients. B. Braun's commitment to innovation in medical devices and solutions contributes to their presence in the global STSG market.
|
GOULIAN Dermatome, 180 mm
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
|
|
5.
|
AlloSource
|
AlloSource is a nonprofit organization specializing in the development and distribution of human tissue allografts for medical use. Their PureSkin® human skin allografts are temporary dressings containing cells and biologic factors native to human skin, used with critical burn patients to aid in infection control, fluid maintenance, and pain control, as well as to conserve the use of precious autograft skin.
|
|
North America
|
In October 2022, AlloSource has been awarded a multi-year contract by BARDA, a division of ASPR in HHS, to establish significant inventories of donated skin for treating burn patients following mass casualty events. This contract enhances AlloSource's capabilities to respond effectively to emergency burn care needs and strengthens its partnership with federal healthcare agencies.
|
Conclusion
The global split-thickness skin grafts (STSG) market for burns and extensive skin loss is positioned for continued expansion, driven by the rising prevalence of burn injuries and the need for effective skin reconstruction solutions. Innovations in surgical techniques and enhanced grafting methods are improving patient outcomes and increasing the adoption of STSGs in clinical practice. While North America remains a key market due to its advanced healthcare infrastructure and technological advancements, the Asia-Pacific region is emerging as a significant growth area, bolstered by rising healthcare investments and a larger patient demographic. Key market players are actively pursuing product development and strategic collaborations to enhance their competitive edge.
